Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02684227
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:43.869233+00:00
Published At
2025-03-19T00:00:00+00:00
Record Updated At
2025-03-19
Results Posted At
2025-03-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Uterine Corpus Carcinoma", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IIIA Uterine Corpus Cancer AJCC v7", "Stage IIIB Uterine Corpus Cancer AJCC v7", "Stage IIIC Uterine Corpus Cancer AJCC v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Stage IVA Uterine Corpus Cancer AJCC v7", "Stage IVB Uterine Corpus Cancer AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-03-19"
protocolSection.identificationModule.nctId
"NCT02684227"
protocolSection.identificationModule.officialTitle
"A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-03-19"

Study condition terms

  • Recurrent Endometrial Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Uterine Corpus Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage III Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVA Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVB Uterine Corpus Cancer AJCC v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.